NOVN - ノバン (Novan Inc.) ノバン

 NOVNのチャート


 NOVNの企業情報

symbol NOVN
会社名 Novan Inc (ノバン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ノーバン(Novan Inc)は後期段階の医薬品会社である。同社は一酸化窒素プラットフォームを使用することによって治療法の開発・商業化に従事する。同社は調整可能な新規化学物質(NCEs)の操作を可能とするNitricil技術によって候補製品を開発する。同社の製剤サイエンスは非活性成分を使用することによって皮膚に応用される時に一酸化窒素の放出のさらなる調整を可能とする。同社は第3相尋常性座瘡の治療用SB204、第2相外生殖器・肛門疣贅の治療用製品候補SB206、皮膚・爪の真菌感染の治療用試験中局所的な抗真菌剤SB208を開発している。同社は炎症性皮膚疾患の治療用SB204を開発している。同社のパイプラインはまた局所的クリーム製品候補SB414を含む。   ノバンは米国の医薬品企業。主に臨床段階で、皮膚科の疾患に対する治療薬の開発・商業化に従事する。皮膚の免疫反応で不可欠な一酸化窒素を用いて治療するプラットフォ―ムを開発し、同社パイプラインには「SB206」、「SB208」、「SB414」などがある。本社はノ―スカロライナ州ダ―ラム。   Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.
本社所在地 4105 Hopson Road Morrisville NC 27560 USA
代表者氏名 Robert A. Ingram ロバートA.イングラム
代表者役職名 Independent Chairman of the Board
電話番号 +1 919-485-8080
設立年月日 38718
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 59人
url www.novan.com
nasdaq_url https://www.nasdaq.com/symbol/novn
adr_tso
EBITDA EBITDA(百万ドル) -30.26500
終値(lastsale) 2.63
時価総額(marketcap) 68486362.46
時価総額 時価総額(百万ドル) 65.23131
売上高 売上高(百万ドル) 2.67800
企業価値(EV) 企業価値(EV)(百万ドル) 52.27231
当期純利益 当期純利益(百万ドル) -28.42800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novan Inc revenues increased 26% to $1.3M. Net loss decreased 40% to $12.8M. Revenues reflect License and collaboration revenue increase of 33% to $1.3M. Lower net loss reflects Change in fair value of warrant increase from $0K to $4.3M (income) General and administrative - Balancing decrease of 28% to $4.8M (expense) Research and Development - Balancing decrease of 10% to $11.8M (expense).

 NOVNのテクニカル分析


 NOVNのニュース

   Novartis : Alcon Pay $347 Million to Settle Bribery Probes -- Update | MarketScreener  2020/06/25 21:54:00 MarketScreener
By Dylan Tokar and Micah Maidenberg Novartis AG and a former subsidiary of the Swiss drugmaker agreed to pay a combined $347 million to resolve allegations that the companies ran schemes to… | June 25, 2020
   Swiss Pharma Giant Novartis to Pay $112Mln to Settle Bribery Charges - US Regulator  2020/06/25 18:40:09 UrduPoint
   Novartis to pay $336 mn in US settlements on bribes  2020/06/25 18:36:14 RTL Today
   Novartis Units to Pay $347 Million to Resolve U.S. Bribery Probe - BNN Bloomberg  2020/06/25 17:26:50 BNN Bloomberg
Novartis AG and two of its subsidiaries admitted to overseas bribery schemes and agreed to pay about $347 million to settle U.S. criminal and regulatory investigations.
   Novartis, former unit to pay $346 million to resolve US bribery charges | Kathimerini  2020/06/25 17:20:13 ekathimerini.com
Novartis AG and a former unit will pay more than $346 million to resolve US criminal and civil charges they bribed doctors, hospitals and clinics to prescribe their drugs and use their surgical products, US authorities announced on Thursday.
   Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA  2020/05/19 14:52:00 Zacks Investment Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
   Novartis : Zolgensma Gets Conditional EU Approval | MarketScreener  2020/05/19 06:05:03 MarketScreener
By Olivia Bugault Novartis AG said Tuesday that its Zolgensma gene therapy for patients with spinal muscular atrophy has been conditionally approved in Europe. The European Commission… | May 19, 2020
   Regenerative Medicine Industry Outlook to 2025 Featuring Novartis, Vericel, Integra Lifesciences, Mimedx Group, Stryker, Wright Medical, Roche and More  2020/05/14 13:00:00 PR Newswire
DUBLIN, May 14, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Market By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Others), By Application, By Material, By Cell, By Product, By Technique, By Distribution Channel, By Region, Forecast & Opportunities, 2025"…
   Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology  2020/05/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   FDA OKs Novartis' osilodrostat for adrenal gland disorder  2020/03/07 15:40:04 Seeking Alpha
The FDA approves Novartis' (NYSE:NVS) Isturisa (osilodrostat) oral tablets for the treatment of adults with Cushing's disease who either cannot undergo pit
   Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets  2020/03/05 13:00:00 Business Wire
BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences is today debuting with the announcement of a major drug discovery collaboration with Novartis.
   We need short-term launches to keep driving growth: Novartis CEO  2020/03/04 08:13:00 Business Today
One of Novartis' success stories in India has been our emerging market brands approach, which enables us to use a distinctive brand and distinct product presentation to (differentially) price (innovative medicines) for the Indian market
   Sanofi just got its first cancer drug approved in a decade. Here's the pharma giant's plan to rejoin the fight against cancer under new CEO Paul Hudson.  2020/03/03 17:51:00 Business Insider
The French drugmaker Sanofi has officially re-entered oncology, as the Food and Drug Administration approved the multiple myeloma treatment Sarclisa on Monday. Sanofi's last new cancer drug was a chemotherapy approved a decade ago. Under new leadership, the company plans to advance several more cancer therapies, a top Sanofi executive told Business Insider. "Sarclisa is our re-entry into oncology," Sanofi's development leader Dietmar Berger said in an interview. "You see a very meaningful pipeline behind that." In his first few months as CEO, Paul Hudson has begun shaking up the $120 billion pharma giant. In December, he announced Sanofi will stop diabetes and cardiovascular research , while inking a $2.5 billion deal to acquire Synthorx and expand its immuno-oncology pipeline. Click here for more BI Prime stories . Sanofi is back in the fight against cancer. On Monday, the French pharmaceutical giant won US approval for Sarclisa, a therapy for a type of blood cancer called multiple myeloma.
   Sandoz to pay $195M in price-fixing case  2020/03/03 12:45:58 Seeking Alpha
Novartis (NYSE:NVS) unit Sandoz has agreed to pay a criminal penalty of $195M to settle a federal generic drug price-fixing case. The U.S. Department of Ju

 関連キーワード  (医薬品 米国株 ノバン NOVN Novan Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)